BACKGROUND: Measles and congenital rubella syndrome remain significant causes of morbidity and mortality despite available vaccines. HIV-infected youth may be at increased risk of measles because of greater waning immunity after vaccination. At a population level, they constitute a potentially large pool of susceptibles to measles and rubella. More data among HIV-infected youth in sub-Saharan Africa are needed to guide vaccination policy and control strategies. METHODS: This cross-sectional study was nested within 2 ongoing studies of malaria and HIV in Zambia. Dried blood spot cards from youth (5-15 years) in these studies from 2009 to 2013 were tested for IgG antibodies to measles and rubella viruses. HIV-uninfected youth, HIV-infected treatment-naive youth and HIV-infected youth receiving antiretroviral therapy (ART) were compared. RESULTS: A total of 617 HIV-uninfected, 144 HIV-infected treatment-naive and 128 HIV-infected youth receiving ART were included in this study. The proportion seropositive for measles virus was significantly higher among HIV-uninfected youth (92.5%) compared with HIV-infected treatment-naive youth (74.1%) and HIV-infected youth receiving ART (71.9%). No differences by age were observed. The proportion seropositive for rubella virus was significantly higher among HIV-uninfected youth (54.7%) compared with HIV-infected treatment-naive youth (41.7%) and HIV-infected youth receiving ART (49.6%), with increases observed by age for all groups. CONCLUSIONS: Measles seroprevalence was lower among HIV-infected than uninfected youth, consistent with waning immunity after measles vaccination. HIV-infected youth would benefit from revaccination. Half of all youth in rural Zambia were susceptible to rubella and may need targeting for catch-up rubella campaigns when measles-rubella vaccine is introduced.
BACKGROUND:Measles and congenital rubella syndrome remain significant causes of morbidity and mortality despite available vaccines. HIV-infected youth may be at increased risk of measles because of greater waning immunity after vaccination. At a population level, they constitute a potentially large pool of susceptibles to measles and rubella. More data among HIV-infected youth in sub-Saharan Africa are needed to guide vaccination policy and control strategies. METHODS: This cross-sectional study was nested within 2 ongoing studies of malaria and HIV in Zambia. Dried blood spot cards from youth (5-15 years) in these studies from 2009 to 2013 were tested for IgG antibodies to measles and rubella viruses. HIV-uninfected youth, HIV-infected treatment-naive youth and HIV-infected youth receiving antiretroviral therapy (ART) were compared. RESULTS: A total of 617 HIV-uninfected, 144 HIV-infected treatment-naive and 128 HIV-infected youth receiving ART were included in this study. The proportion seropositive for measles virus was significantly higher among HIV-uninfected youth (92.5%) compared with HIV-infected treatment-naive youth (74.1%) and HIV-infected youth receiving ART (71.9%). No differences by age were observed. The proportion seropositive for rubella virus was significantly higher among HIV-uninfected youth (54.7%) compared with HIV-infected treatment-naive youth (41.7%) and HIV-infected youth receiving ART (49.6%), with increases observed by age for all groups. CONCLUSIONS:Measles seroprevalence was lower among HIV-infected than uninfected youth, consistent with waning immunity after measles vaccination. HIV-infected youth would benefit from revaccination. Half of all youth in rural Zambia were susceptible to rubella and may need targeting for catch-up rubella campaigns when measles-rubella vaccine is introduced.
Authors: S M Arpadi; L E Markowitz; A L Baughman; K Shah; H Adam; A Wiznia; G Lambert; J Dobroszycki; J L Heath; W J Bellini Journal: Pediatrics Date: 1996-05 Impact factor: 7.124
Authors: R F Helfand; H L Keyserling; I Williams; A Murray; J Mei; C Moscatiello; J Icenogle; W J Bellini Journal: J Med Virol Date: 2001-12 Impact factor: 2.327
Authors: A Vigano; S Vella; M Saresella; A Vanzulli; D Bricalli; S Di Fabio; P Ferrante; M Andreotti; M Pirillo; L G Dally; M Clerici; N Principi Journal: AIDS Date: 2000-02-18 Impact factor: 4.177
Authors: Omphile E Simani; Alane Izu; Avy Violari; Mark F Cotton; Nadia van Niekerk; Peter V Adrian; Shabir A Madhi Journal: AIDS Date: 2014-02-20 Impact factor: 4.177
Authors: Lindsey Rearigh; Jennifer O'Neill; Maureen Kubat; Harlan Sayles; Susan Swindells; Sara H Bares Journal: Open Forum Infect Dis Date: 2020-09-12 Impact factor: 3.835
Authors: Eleonora A M L Mutsaerts; Marta C Nunes; Martijn N van Rijswijk; Kerstin Klipstein-Grobusch; Diederick E Grobbee; Shabir A Madhi Journal: EClinicalMedicine Date: 2018-07-02
Authors: Kyla Hayford; Simon Mutembo; Andrea Carcelen; Hellen K Matakala; Passwell Munachoonga; Amy Winter; Jane W Wanyiri; Kelly Searle; Francis D Mwansa; Angels Mwiche; Caroline Phiri; Chris Book; Philip E Thuma; William J Moss Journal: Vaccine Date: 2019-03-21 Impact factor: 3.641
Authors: Christine Prosperi; Ojas Kaduskar; Gajanan N Sapkal; Kyla Hayford; Vaishali Bhatt; Alvira Z Hasan; Jeromie W Vivian Thangaraj; Muthusamy S Kumar; R Sabarinathan; Saravana Kumar; Augustine Duraiswamy; Gururaj Rao Deshpande; Ullas Padinjaremattathil Thankappan; Sanjay L Chauhan; Ragini N Kulkarni; Avi Kumar Bansal; Itta K Chaaithanya; Neha R Salvi; Sandeep Sharma; William J Moss; Lucky Sangal; Nivedita Gupta; Manoj V Murherkar; Sanjay M Mehendale Journal: mSphere Date: 2021-07-14 Impact factor: 4.389